The intelligence layer for uncompromising biopharma teams
DrugBank's Knowledge Graph is the connected intelligence core built from 20 years of curated biomedical data. Every datapoint traces back to its source, updates continuously, and is ready for AI and human discovery.
- Drugs
- Targets and enzymes
- Conditions
- Structured indications
- Clinical trials
- Companies
- Adverse effects
- Drug interactions
- Pathways
- Biomarkers
- 150M+ data points.
- Twenty years of curated biomedical data, structured so a scientist and an agent get the same answer from the same question.
- Billions of directional relationships.
- The graph records a relationship's direction, not just that a connection exists. Inhibiting and inducing aren't the same.
- Causal links, not co-occurrence.
- Terms are connected when a mechanism is real, not because terms appear together in an abstract, a distinction most graphs skip.
- Pipeline coverage of 10,000+ companies.
- Every asset, phase, and sponsor is tied to the underlying biology, so commercial and scientific context show up in one query.
- Traceable to primary source.
- Every datapoint carries its evidence lineage, so the answer holds up when your VP, your partner, or a regulator asks where it came from.
- Engineered to close the gaps.
- Relationships are built in-house to fill the curation gaps left by the industry that stall hard and complex queries.
Explore with confidence. Decide with conviction.
One connected graph means completeness is guaranteed, not assumed.
- Trust that whitespace is a finding, not missing data
- Explore the complete scientific and commercial picture
- Make go/no-go calls based on the full landscape
- 20-year
- track record
- 1,500+
- institutions
- 65,000+
- citations
- $10B+
- in research enabled
- 10/20
- top pharma companies
Knowledge Engine
Intelligence this nuanced isn't built overnight
Run continuously and overseen by expert curators, the Knowledge Engine delivers complete, correct, fresh, and traceable data directly to the graph.
Capture & Ingest
Continuous data point ingestion from a broad set of primary and regulatory sources
Engineer & Structure
Aggregate, harmonize, and resolve entities to a single record and connect to 20+ ontologies
Validate & Review
Ongoing quality control overseen by biostatisticians to maintain standards for millions of records
Engineered beyond the industry's blind spots
Sponsors resolved to their true owner
A sponsor's name on a filing isn't always who's behind it, and untangling that takes more than one lookup.
- One company can rename itself multiple times over a trial's history.
- One name can front a dozen affiliates, each filing under a different label.
Trial registries only ever show a piece of this. DrugBank pulls the rest from SEC filings, corporate registries, and M&A records, then normalizes and connects them, drawing on SEC records that reach back over a century.
Sponsor names as filed
- AstraZeneca
- Astra USA
- MedImmune LLC
- Cambridge Antibody Technology
- Alexion Pharmaceuticals, Inc.
- Achillion, a wholly owned subsidiary of Alexion
+ 31 more trial sponsor strings
Resolved against
- Trial registries
- SEC filings
- Corporate registries
- M&A records
- Merger Astra
- Independent subsidiary Alexion Pharmaceuticals
- Absorbed subsidiary MedImmune
- Absorbed subsidiary Trimeris
- Absorbed subsidiary Portola Pharmaceuticals
+ 17 more resolved entities
Any ID unlocks the full record
Every ID system was built for a different job, and none of them talk to each other on their own.
- ChEMBL, PubChem, RxNorm, ATC, and UNII each cover their own slice, with no shared structure to move between them.
- Mapping one to another usually means a manual lookup table that breaks the moment coverage shifts.
DrugBank engineers its own ontologies that are purpose-built for the problems this data needs to solve, then maps every major ID system back to them. Start from any ID and you'll land straight on the full drug record.
Development code names
- PF-06439535
- ABP 215
- CT-P16
- + 41 more
Nonproprietary names
- bevacizumab-awwb
- Bevacizumab-bvzr
- Bevacizumab beta
- + 16 more
Brand names
- Avastin
- Mvasi
- Zirabev
- + 43 more
Database identifiers
- CHEMBL1201583
- RxCUI 253337
- UNII 2S9ZZM9Q9V
- + 9 more
DrugBank record
Bevacizumab
DB00112
Full structure for every indication
On-label, off-label, or investigational only tells you the regulatory status. It doesn't tell you how it actually works.
- Every indication carries its own dose, region, patient population, and combination use, and none of that shows up in a status label.
- Diseases don't exist in isolation, and the relationships between them matter as much as the indication itself.
DrugBank builds its own disease ontologies, designed for how indications actually vary, then maps the relationships between them. That structure makes it possible to pull the full indication record and filter or aggregate those fields directly.
REZDIFFRA is indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).
Across 8 trials
NASH - Nonalcoholic Steatohepatitis Non-alcoholic Steatohepatitis Non-Alcoholic Fatty Liver Disease MASH - Metabolic Dysfunction-Associated Steatohepatitis MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease + 2 more spellings
adjunct_therapy_in_treatment_of
| Indication 1 | Indication 2 | |
|---|---|---|
| Condition | Advanced Liver Fibrosis | moderate Liver Fibrosis |
| Associated with | Metabolic Dysfunction-associated Steatohepatitis (MASH) | Metabolic Dysfunction-associated Steatohepatitis (MASH) |
| Excludes | Decompensated Cirrhosis | Decompensated Cirrhosis |
| Given with | Diet, Exercise | Diet, Exercise |
| Population | adult | adult |
| Region | US | US |
Get answers you can trust, every time.
| Drug | As published | Normalized |
|---|---|---|
| Glucagon | 26 minutes | 0.43 h |
| Pramlintide | 48 minutes | 0.80 h |
| Exenatide | 2.4 hours | 2.4 h |
| Liraglutide | 13 hours | 13 h |
| Weekly dosing threshold · 24 h | ||
| Dulaglutide | 3.75 days | 89.9 h |
| Tirzepatide | 5 days | 120 h |
| Semaglutide | 168 hours | 168 h |